Lv0
0 积分 2024-06-03 加入
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
5个月前
已完结
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
5个月前
已完结
Development of a PCSK9-targeted nanoparticle vaccine to effectively decrease the hypercholesterolemia
5个月前
已完结
Association between the Sarcopenia-related traits and Parkinson's Disease: A Bidirectional Two-Sample Mendelian Randomization Study
5个月前
已完结
Accelerating diabetic wound healing by ROS-scavenging lipid nanoparticle–mRNA formulation
5个月前
已完结
皖公网安备34019202002308
